Stocktoria
QuidelOrtho Corp QDEL
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1991-02-01
QuidelOrtho Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Operating margin | -33.7% | -70.5% | 4.6% | 25.8% | 53.3% |
| Net margin | -41.5% | -73.7% | -0.3% | 16.8% | 41.5% |
| FCF margin | -3.0% | -4.0% | 2.4% | 22.8% | 30.2% |
| Return on assets | -19.6% | -31.9% | -0.1% | 6.2% | 29.0% |
| Return on equity | -58.9% | -68.8% | -0.2% | 11.1% | 36.5% |
| Debt / equity | 1.40× | 0.83× | 0.48× | 0.54× | — |
| Current ratio | 1.50 | 1.22 | 1.57 | 1.56 | 4.45 |
| Revenue growth | -1.9% | -7.2% | -8.2% | 92.3% | — |
Source: SEC EDGAR filings · CIK 0001906324 · as of 2025-12-28. Facts from filings plus Stocktoria's own computed scores — not investment advice.